Robert Deans,
Executive Vice President
Dr. Deans is responsible for regenerative medicine technology development at Athersys Inc. and its European subsidiary, ReGenesys. Athersys is developing cell therapeutics based on adherent stem cells (MultiStem) isolated from adult bone marrow. Athersys has active Phase II clinical development activity in acute myocardial infarct, stroke, ulcerative colitis, and for adjunctive therapy of allogeneic bone marrow transplant. Dr. Deans has more than 20 years of experience in stem cell therapeutics, having previously served at Osiris Therapeutics as VP of Research. Dr. Deans was previously Director of R&D at Baxter Healthcare, where he developed biological components of the Isolex300i hematopoietic stem cell purification platform. In addition, Dr. Deans served on the faculty at USC Medical School from 1984 to 1992. He holds degrees from MIT and the University of Michigan, and postdoctoral training in molecular immunology at UCLA.
|
|
|
